Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03334539 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
A Phase 2 study, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT03334539 is a Phase 2 study that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 150 participants.
The verdict
NCT03334539, a Phase 2 study, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Interventions
- BIOLOGICAL HL036 ophthalmic solution
- OTHER Placebo vehicle solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-11-05 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03334539
The ClinicalTrials.gov registry entry for NCT03334539 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HanAll BioPharma Co., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HL036 ophthalmic solution is the first listed.
NCT03334539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03334539 about?
NCT03334539 is a clinical study titled "A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes". The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT03334539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-11-05. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT03334539?
The interventions under investigation include: HL036 ophthalmic solution (BIOLOGICAL), Placebo vehicle solution (OTHER).
Who is sponsoring clinical trial NCT03334539?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.